UK-based life science investor Syncona has launched a new company – Slingshot Therapeutics – with a mission to find promising projects in academia and translate them into full-blown development projects. Slingshot, which was incorporated in August, starts life with £12.5 million (around $15 million) in funding from Syncona and a lead development programme in inflammatory diseases. Source: Pharmaphorum 14/11/2024